Literature DB >> 14749528

Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses.

Juyang Kim1, Sun Phil Choi, Soojin La, Jeong-Sun Seo, Kack Kyun Kim, Seok Hyun Nam, Byungsuk Kwon.   

Abstract

4-1BB, a transmembrane molecule, member of the tumor necrosis factor receptor superfamily, is an important costimulatory molecule in the immune response, plays a key role in the clonal expansion and survival of CD8(+) T cells. In this study, we investigated 4-1BB regulation of CD4(+) T cell responses using 4-1BB transgenic (TG) mice that constitutively expressed 4-1BB on mature T cells. We first showed that CD4(+) T cells of 4-1BB TG mice had more sustained proliferative capacity in response to TCR/4-1BB stimulation in vitro compared to WT mice. Secondly, 4-1BB TG mice exhibited a more elevated contact hypersensitivity (CHS) response mediated by CD4+ Th1 cells due to more vigorous expansion of and apoptotic inhibition of CD4(+) T cells. Finally, CD4(+) T cells of 4-1BB TG mice had a heightened capacity for T cell priming. Overall, our results demonstrate the involvement of 4-1BB in CD4(+) Th1 cell responses by regulating the clonal expansion and survival of CD4(+) T cells as seen in CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14749528     DOI: 10.1038/emm.2003.66

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  5 in total

1.  Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.

Authors:  Sung Hee Yoon; Sun Ok Yun; Jung Yong Park; Hee Yeun Won; Eun Kyung Kim; Hyun Jung Sohn; Hyun Il Cho; Tai Gyu Kim
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

2.  The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Authors:  Kritika Kachapati; David E Adams; Yuehong Wu; Charles A Steward; Daniel B Rainbow; Linda S Wicker; Robert S Mittler; William M Ridgway
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

Review 3.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

4.  Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.

Authors:  Tao Wang; William C Hartner; James W Gillespie; Kulkarni P Praveen; Shenghong Yang; Leslie A Mei; Valery A Petrenko; Vladimir P Torchilin
Journal:  Nanomedicine       Date:  2013-09-09       Impact factor: 5.307

Review 5.  Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors.

Authors:  Daniele E Mascarelli; Rhubia S M Rosa; Jessica M Toscaro; Isadora F Semionatto; Luciana P Ruas; Carolinne T Fogagnolo; Gabriel C Lima; Marcio C Bajgelman
Journal:  Front Cell Dev Biol       Date:  2021-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.